BGLC vs HCA · rev $99.0K vs P/E 17, rev $75.60B
BioNexus Gene Lab Corp Common stock (BGLC) versus HCA Holdings Inc (HCA) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
HCA Holdings Inc (HCA) is a medical care facilities company listed on US.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported HCA revenue for 2025-12-31 was $75.60B. Net income was $6.78B. Revenue was up 7.1% from 2024-12-31 to 2025-12-31. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
BGLC currently screens at market cap $6.1M. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
Not investment advice. Open the BGLC and HCA stock pages for the full models.
Not investment advice.